-
Product Insights
Pfizer Inc/ Sobi – Savski Marof Biotechnology Production Plant – City of Zagreb
Equip yourself with the essential tools needed to make informed and profitable decisions with our Pfizer Inc/ Sobi - Savski Marof Biotechnology Production Plant - City of Zagreb report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Thematic Analysis
New![]()
Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q2 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Pharma Sector
-
Company Profile
![]()
Swedish Orphan Biovitrum AB – Company Profile
Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner...
Add to Basket -
Product Insights
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol intake, injury to joints, long-standing kidney disease, and high intake of foods rich in purines. The Gouty Arthritis (Gout)...
-
Sector Analysis
Sweden Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape
The Sweden pharmaceutical market size was $6.2 billion in 2021. Likewise, the Swedish medical devices market size was $2.1 billion in 2021 and is expected to achieve a CAGR of more than 3% during 2022-2027. The growth in the pharmaceutical market is attributed to the growing aging population; lifestyle-related disease conditions such as diabetes and obesity; and increased prevalence of chronic diseases such as cardiovascular conditions, stroke, and cancer. The Sweden healthcare market research report is an essential source of...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Paroxysmal Nocturnal Hemoglobinuria include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache, and shortness of breath. Its treatment includes surgery, chemotherapy, and radiation therapy. Key Targets Complement C5, Complement Factor D, Complement C3, Leukotriene B4, Complement Factor B, Mannan Binding Lectin Serine Protease 1, and Properdin Key Mechanisms of Action Complement C5 Inhibitor, Complement Factor D Inhibitor, Complement C3 Inhibitor, Leukotriene B4 Inhibitor, Complement Factor B Inhibitor, Mannan Binding Lectin Serine Protease 1 Inhibitor,...
-
Product Insights
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from the nose, and superficial bleeding into the skin that appears as a rash of pinpoint-sized reddish-purple spots, usually on the lower legs. The Idiopathic Thrombocytopenic Purpura Drugs in Development market research report provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. The report...
-
Sector Analysis
Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. RSV infection generally causes mild flu-like symptoms, which can include a runny nose, lowered appetite, fever, coughing, and/or sneezing. Irritability and difficulty breathing may be the only symptoms shown by very young infants with RSV. RSV is a viral infection that is transmitted through contact with droplets in the air or on surfaces like doorknobs, tabletops,...
-
Sector Analysis
Supportive Care in Cancer – Comprehensive Overview, Pipeline Products, Research and Development Strategies and Unmet Needs
Supportive care in cancer is an evolving discipline of medicine that is critical for holistic management of patients with cancer. With significant advancements being made in treatment of cancer particularly through development of immuno-oncology (IO) and targeted therapies, it is of equal significance to focus on supportive care in cancer so as to ensure that patients are able to complete the treatment cycle for the primary cancer as well as to enhance their quality of life. The report leverages on...
-
Product Insights
Hemophilia B Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hemophilia B Global Clinical Trials Review, H2, 2016" provides an overview of Hemophilia B clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hemophilia A Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2016" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,501 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan),...
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...
-
Product Insights
Hemophilia A Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hemophilia B Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Hemophilia B Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia B clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
PharmaFocus: Supportive Care in Oncology
Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA). There is a consensus among KOLs across the 7MM that supportive oncology had not been given much priority by physicians and institutions in...
-
Sector Analysis
PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026
Hemophilia A and B are rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, and are characterized by the failure of blood to form normal clots after damage to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.